Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Cell body

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44341   clinical trials with a EudraCT protocol, of which   7370   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    1,412 result(s) found for: Cell body. Displaying page 67 of 71.
    «« First « Previous 63  64  65  66  67  68  69  70  71  Next»
    EudraCT Number: 2016-004750-15 Sponsor Protocol Number: AIO-STS-0415 Start Date*: 2017-10-06
    Sponsor Name:AIO-Studien-gGmbH
    Full Title: A randomized phase II study of Durvalumab (MEDI4736) and Tremelimumab compared to doxorubicin in patients with advanced or metastatic soft tissue sarcoma.
    Medical condition: advanced or metastatic soft tissue sarcoma
    Disease: Version SOC Term Classification Code Term Level
    15.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10041299 Soft tissue sarcomas HLGT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10075333 Soft tissue sarcoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2011-006013-34 Sponsor Protocol Number: 115884 Start Date*: 2013-01-11
    Sponsor Name:GlaxoSmithKline Biologicals
    Full Title: A phase III, open, controlled, multi-centric study to evaluate the immunogenicity, safety and reactogenicity of GSK Biologicals' 10-valent pneumococcal conjugate vaccine when administered to childr...
    Medical condition: Active immunization against disease caused by Streptococcus pneumoniae in children 2-17 years of age who are at increased risk of pneumococcal infection.
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004862 10042197 Streptococcus pneumoniae septicaemia LLT
    14.1 100000004862 10042195 Streptococcus pneumoniae pneumonia LLT
    14.1 100000004862 10054642 Streptococcus pneumoniae septicemia LLT
    15.1 100000004862 10035648 Pneumococcal pneumonia [Streptococcus pneumoniae pneumonia] LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA PL (Completed)
    Trial results: View results
    EudraCT Number: 2021-001572-42 Sponsor Protocol Number: FCN-159-002 Start Date*: 2021-12-21
    Sponsor Name:Shanghai Fosun Pharmaceutical Industrial Development Co.,Ltd.
    Full Title: A multi-center, open-label, single-arm Phase I dose-escalation and Phase II dose-expansion study to evaluate the safety, tolerability, PK characteristics and anti-tumor activity of FCN-159 in adult...
    Medical condition: Participants diagnosed with Neurofibromatosis NF1-related plexiform neurofibromas (PN) and symptomatic with requirement of systematic therapy per investigator’s judgment. A PN is defined as a neuro...
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004850 10029270 Neurofibromatosis, type 1 (von Recklinghausen's disease) LLT
    Population Age: Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing) IT (Ongoing) PL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2010-019550-40 Sponsor Protocol Number: AMAG-FER-CKD-253 Start Date*: Information not available in EudraCT
    Sponsor Name:AMAG Pharmaceuticals, Inc.
    Full Title: An Open-Label Extension Study of the Safety and Efficacy of Ferumoxytol for the Episodic Treatment of Iron Deficiency Anemia in Pediatric Subjects with Chronic Kidney Disease
    Medical condition: Chronic Kidney Disease
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004857 10064848 Chronic kidney disease LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: DE (Completed) GB (Prematurely Ended) HU (Completed) ES (Completed) RO (Temporarily Halted) LT (Prematurely Ended) BG (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2017-002158-35 Sponsor Protocol Number: IVA_01_ODI_HMPS_17_002 Start Date*: 2017-11-16
    Sponsor Name:Inventiva S.A.
    Full Title: A phase IIa study to investigate safety, Pharmacokinetics, and efficacy of odiparcil in patients 16 years and above with mucopolysaccharidosis (MPS) type VI.
    Medical condition: Mucopolysaccharidosis (MPS) type VI.
    Disease: Version SOC Term Classification Code Term Level
    20.1 10010331 - Congenital, familial and genetic disorders 10028095 Mucopolysaccharidosis IV PT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed) FR (Completed) PT (Completed)
    Trial results: View results
    EudraCT Number: 2018-000666-10 Sponsor Protocol Number: m16-063 Start Date*: 2018-12-17
    Sponsor Name:AbbVie Deutschland GmbH & Co. KG
    Full Title: A Phase 2 Study to Investigate the Safety and Efficacy of ABBV-105 Given Alone or in Combination with Upadacitinib (ABBV-599 Combination) with a Background of Conventional Synthetic DMARDs in Subje...
    Medical condition: Rheumatoid Arthritis
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004870 10039075 Rheumatoid arthritis and associated conditions HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) HU (Completed) BE (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2016-001984-35 Sponsor Protocol Number: M16OPN Start Date*: 2017-06-22
    Sponsor Name:Antoni van leeuwenhoek ziekenhuis
    Full Title: Multicenter Phase 2 Study to Identify of the Optimal neo-Adjuvant Combination Scheme of Ipilimumab and Nivolumab (OpACIN-neo)
    Medical condition: Patients with stage III melanoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025670 Malignant melanoma stage III PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Ongoing) AT (Prematurely Ended) GB (GB - no longer in EU/EEA) DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2019-004706-10 Sponsor Protocol Number: DF1001-001 Start Date*: 2020-11-19
    Sponsor Name:Dragonfly Therapeutics, Inc.
    Full Title: A Phase I/II, First-In-Human, Multi-Part, Open-Label, Multiple-Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, Biological, and Clinical Activity of DF1001 in Patient...
    Medical condition: Locally Advanced or Metastatic Solid Tumors, and Expansion in Selected Indications
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10065252 Solid tumor LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10027476 Metastases HLGT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Trial now transitioned) DK (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2019-001517-16 Sponsor Protocol Number: PQGrass306 Start Date*: 2022-09-29
    Sponsor Name:Allergy Therapeutics (UK) Ltd.
    Full Title: A randomised, double-blind, placebo-controlled clinical trial to evaluate the efficacy and safety of PQ Grass in subjects with seasonal allergic rhinitis and/or rhinoconjunctivitis induced by grass...
    Medical condition: Seasonal allergic rhinitis and/or rhinoconjunctivitis induced by grass pollen exposure
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004853 10001728 Allergic rhinoconjunctivitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) HU (Completed) CZ (Completed) AT (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2017-003351-38 Sponsor Protocol Number: CTX001-111 Start Date*: 2018-07-25
    Sponsor Name:Vertex Pharmaceuticals Incorporated
    Full Title: A Phase 1/2/3 Study of the Safety and Efficacy of a Single Dose of Autologous CRISPR-Cas9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells (hHSPCs) in Subjects with Transfusion-Dependen...
    Medical condition: Transfusion-Dependent β Thalassemia
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10043391 Thalassaemia beta PT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: DE (Trial now transitioned) IT (Completed) GB (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-004143-13 Sponsor Protocol Number: SHP-609-302 Start Date*: 2015-03-19
    Sponsor Name:Shire Human Genetic Therapies, Inc.
    Full Title: An Open Label Extension of Study HGT-HIT-094 Evaluating Long Term Safety and Clinical Outcomes of Intrathecal Idursulfase Administered in Conjunction with Elaprase® in Patients with Hunter Syndrome...
    Medical condition: Hunter syndrome and cognitive impairment
    Disease: Version SOC Term Classification Code Term Level
    20.1 10010331 - Congenital, familial and genetic disorders 10056889 Mucopolysaccharidosis II PT
    20.0 10010331 - Congenital, familial and genetic disorders 10056917 Hunter's syndrome LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male
    Trial protocol: GB (GB - no longer in EU/EEA) ES (Completed) FR (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2016-002312-41 Sponsor Protocol Number: MK-3475-365 Start Date*: 2016-10-22
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc
    Full Title: Phase Ib/II Trial of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (mCRPC) (KEYNOTE-365)
    Medical condition: Metastatic Castration-Resistant Prostate Cancer (mCRPC)
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004864 10076506 Castration-resistant prostate cancer LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: ES (Temporarily Halted) DE (Trial now transitioned) GB (GB - no longer in EU/EEA) FR (Trial now transitioned) SE (Trial now transitioned) DK (Trial now transitioned) IE (Trial now transitioned) IT (Trial now transitioned) PL (Trial now transitioned) NL (Ongoing) AT (Trial now transitioned) FI (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2019-001068-31 Sponsor Protocol Number: 2019/2894 Start Date*: 2019-09-24
    Sponsor Name:Gustave Roussy
    Full Title: High-Risk Neuroblastoma Study 2 of SIOP-Europa-Neuroblastoma (SIOPEN) Randomized, international and multicentric phase 3 study that evaluates and compares 2 treatment strategies in 3 therapeutic p...
    Medical condition: Very High Risk Neuroblastoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029260 Neuroblastoma PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029261 Neuroblastoma NOS LLT
    Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: FR (Trial now transitioned) NL (Trial now transitioned) GB (GB - no longer in EU/EEA) DK (Trial now transitioned) SI (Trial now transitioned) IT (Trial now transitioned) GR (Trial now transitioned) CZ (Trial now transitioned) NO (Trial now transitioned) BE (Trial now transitioned) SE (Ongoing) SK (Trial now transitioned) ES (Ongoing) DE (Ongoing) AT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2011-001254-29 Sponsor Protocol Number: I2R-MC-BIAM Start Date*: 2012-01-24
    Sponsor Name:Eli Lilly and Company
    Full Title: Protocol I2R-MC-BIAM The Impact of LY2605541 versus Insulin Glargine for Patients with Type 2 Diabetes Mellitus Advanced to Multiple Injection Bolus Insulin with Insulin Lispro: a Double-Blind, R...
    Medical condition: Type 2 Diabetes Mellitus
    Disease: Version SOC Term Classification Code Term Level
    14.0 10027433 - Metabolism and nutrition disorders 10049746 Insulin-requiring type II diabetes mellitus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) HU (Completed) SK (Completed) GB (Completed) CZ (Completed) AT (Completed) ES (Completed) LT (Completed) GR (Completed) IT (Completed) DK (Completed) NL (Completed) SI (Completed)
    Trial results: View results
    EudraCT Number: 2009-015578-37 Sponsor Protocol Number: BAY12-8039/11643 Start Date*: 2010-05-10
    Sponsor Name:Bayer HealthCare AG
    Full Title: A randomized, double-blind, multicenter trial to evaluate the safety and efficacy of sequential (intravenous, oral) moxifloxacin versus comparator in pediatric subjects with complicated intraabdomi...
    Medical condition: Complicated intra-abdominal infections (cIAI)
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004862 10056570 Intra-abdominal infection LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: DE (Completed) ES (Prematurely Ended) LV (Completed) LT (Completed) CZ (Completed) BE (Prematurely Ended) HU (Completed) BG (Completed) GR (Completed) Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2006-006437-40 Sponsor Protocol Number: TMC114HIV3006 Start Date*: 2007-02-05
    Sponsor Name:Janssen-Cilag International NV
    Full Title: A randomised, controlled, opel-label trial to compare the efficacy, safety and tolerability of a treatment simplification by darunavir/ritonavir (DRV/r) 800/100 mg O.D. versus a triple combination ...
    Medical condition: HIV-1
    Disease: Version SOC Term Classification Code Term Level
    8.1 10020161 HIV infection LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) GB (Completed) HU (Completed) DK (Completed) DE (Completed) PT (Completed) ES (Completed) AT (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2012-003483-46 Sponsor Protocol Number: 10-0060+EU-Appendix5.0,11.12.2014 Start Date*: 2013-11-12
    Sponsor Name:University of Florida Board of Trustees
    Full Title: Impact of Aggressive Empiric Antibiotic Therapy and Duration of Therapy on the Emergence of Antimicrobial Resistance during the Treatment of Hospitalized Subjects with Pneumonia Requiring Mechanica...
    Medical condition: pneumonia
    Disease: Version SOC Term Classification Code Term Level
    17.1 10021881 - Infections and infestations 10060946 Pneumonia bacterial PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) ES (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2012-001399-12 Sponsor Protocol Number: MORAb-004-203-STS Start Date*: 2014-01-02
    Sponsor Name:Morphotek Inc.
    Full Title: A Study of the Safety and Efficacy of the Combination of Gemcitabine and Docetaxel with MORAb-004 in Metastatic Soft Tissue Sarcoma
    Medical condition: Metastatic Soft Tissue Sarcoma
    Disease: Version SOC Term Classification Code Term Level
    15.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10041299 Soft tissue sarcomas HLGT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) NL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2009-014842-28 Sponsor Protocol Number: SM101-201-itp-09 Start Date*: 2010-01-06
    Sponsor Name:SuppreMol GmbH
    Full Title: A Randomised, Multi-centre, Double-Blind, Placebo-Controlled, Single/Multiple Dose Escalation Phase Ib/IIa Clinical Trial to Investigate the Safety and Efficacy of Recombinant Human Soluble Fc-gamm...
    Medical condition: Idiopathic Thrombocytopenic Purpura
    Disease: Version SOC Term Classification Code Term Level
    12.0 10021245 Idiopathic thrombocytopenic purpura LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) DE (Completed) PL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2015-005513-72 Sponsor Protocol Number: B7451006 Start Date*: 2016-07-21
    Sponsor Name:Pfizer Inc, 235 East 42nd Street, New York, NY 10017
    Full Title: A PHASE 2B RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL, MULTICENTER, DOSE-RANGING, STUDY TO EVALUATE THE EFFICACY AND SAFETY PROFILE OF PF-04965842 IN SUBJECTS WITH MODERATE TO SEVERE AT...
    Medical condition: ATOPIC DERMATITIS
    Disease: Version SOC Term Classification Code Term Level
    19.0 10021428 - Immune system disorders 10021428 Immune system disorders SOC
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) HU (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 63  64  65  66  67  68  69  70  71  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu Jun 12 14:52:12 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA